Carfilzomib is under clinical development by Amgen and currently in Phase II for Cutaneous T-Cell Lymphoma. According to GlobalData, Phase II drugs for Cutaneous T-Cell Lymphoma have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Carfilzomib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Carfilzomib overview

Carfilzomib (Kyprolis) is an antineoplastic agent. It is formulated as Lyophilized powder for solution and solution for intravenous/ intravenous drip route of administration. Carfilzomib is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. Kyprolis is also used in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. Kyprolis in combination with daratumumab and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior therapy.

Carfilzomib is under development for the treatment of neuroendocrine cancer, newly diagnosed primary plasma cell leukemia, kidney and lung transplantation, amyloidosis, hematological malignancies including lymphoma, T-Cell lymphomas, relapsed or refractory peripheral T-cell lymphoma, and T-cell acute lymphoblastic leukemia, cutaneous T-cell lymphoma, Waldenstrom Macroglobulinemia, relapsed/refractory multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma (DLBCL). It was also under development for Hodgkin's disease, relapsed/refractory acute myeloid leukemia, refractory renal cell carcinoma, castration-resistant prostate cancer (who have previously received chemotherapy and androgen inhibitors), ovarian cancer, small-cell lung cancer, non-small cell lung cancer, relapsed/refractory mantle cell lymphoma, chronic lymphocytic leukemia (CLL), marginal zone B-cell lymphoma and chronic graft versus host disease.

Amgen overview

Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in six focused disease areas including cardiovascular diseases, oncology/hematology, inflammation, bone health, neurological disorders and nephrology. The company develops products using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels such as print, television and online media. Amgen is headquartered in Thousand Oaks, California, the US.

For a complete picture of Carfilzomib’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.